Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
Merkel Cell Carcinoma|Cutaneous Squamous Cell Carcinoma
DRUG: Cemiplimab-Rwlc
Number of Participants With Adverse Events Related to Study Treatment, Number of participants with adverse events after receiving at least one dose of cemiplimab, Beginning of treatment to end of follow up, up to 3 years
Relapse Free Survival, Relapse Free Survival (RFS) is defined as the time from study enrollment until disease recurrence or death., Up to 3 years|Overall Survival, Overall Survival (OS) is defined as the time from study enrollment until death., Up to 3 years
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).